BiotechTube
Pear Bio

Pear Bio

London, United Kingdom· Est.
pearbio.com
Is this your company? Claim your profile to update info and connect with investors.
Claim profile

Private Company

Total funding raised: $11.2M

Overview

Pear Bio is a private, pre-revenue biotech developing a functional precision oncology platform that bridges diagnostics and drug discovery. Its core technology involves generating 3D immune-microtumors from patient biopsies to empirically test multiple therapies in parallel, aiming to predict clinical response and match patients with effective treatments. The company is currently running observational clinical trials in triple-negative breast cancer (TNBC) to validate its predictive assay while simultaneously using its platform for novel target identification. Pear Bio operates at the intersection of personalized testing services and therapeutic development, targeting a significant unmet need in oncology.

Oncology

Technology Platform

Proprietary 3D cell culture system that creates 'immune-microtumors' from patient biopsies for ex vivo functional drug testing and multi-omic analysis for target discovery.

Funding History

2
Total raised:$11.2M
Series A$10M
Seed$1.2M

Opportunities

The significant unmet need in hard-to-treat cancers like TNBC, where current therapies have variable efficacy, creates a large market for a predictive functional test.
Success in validation could enable rapid expansion into other aggressive cancer types.
The integrated model of diagnostics feeding drug discovery offers a unique opportunity to identify high-confidence novel therapeutic targets.

Risk Factors

The major risk is the clinical validation of the ex vivo platform's predictive accuracy, as 3D cultures may not fully replicate in vivo complexity.
Commercialization faces challenges including tissue acquisition logistics, test turnaround time, cost, and payer reimbursement.
As a pre-revenue biotech, it is dependent on investor funding to sustain its dual diagnostic and therapeutic development efforts.

Competitive Landscape

Pear Bio competes in the functional precision oncology space against companies like Exscientia (AI-driven but also employing patient-derived models), Kiyatec, and other ex vivo testing platforms. It also faces indirect competition from genomic profiling firms (e.g., Foundation Medicine, Guardant) and a growing number of AI-based prediction tools. Its differentiation lies in the specific focus on 3D immune-microtumors and the direct integration of diagnostic data into therapeutic discovery.

More companies in United Kingdom →